ProKidney Stock Soars 67.56% on Positive Trial Data

On July 9, 2025, ProKidney's stock price surged by 67.56% in pre-market trading, driven by the release of promising mid-stage trial data for its potential treatment for chronic kidney disease.

ProKidney's shares have seen a significant boost following the announcement of positive topline results from its Phase 2 REGEN-007 trial. The trial evaluated rilparencel, a potential treatment for chronic kidney disease in patients with diabetes. The therapy demonstrated statistically significant improvements in kidney function, which has bolstered confidence in its ongoing Phase 3 PROACT 1 trial. ProKidney is preparing to submit the full REGEN-007 data for presentation at the 2025 ASN Kidney Week and is also gearing up for an upcoming FDA Type B meeting regarding accelerated approval pathways.

The positive trial results have sparked a surge in investor interest, with ProKidney's stock price experiencing a monumental increase. The company's shares have traded near their 52-week high, reflecting the market's optimism about the potential of rilparencel. However, despite the promising data, ProKidney remains a high-risk investment, given the uncertainties associated with clinical trials and regulatory approvals.